drugset
drugset / Trial / NCT06345599

PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)

NCT06345599 ↗

Phase 1/2 Not yet recruiting 66 enrolled Second Affiliated Hospital of Soochow University
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn about Phase I+Phase II Clinical Study of PRaG Therapy in Combination With Chemotherapy (AG Regimen) for Neoadjuvant Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study).The main question it aims to answer is to investigate the safety and efficacy of the PRaG treatment modality combined with chemotherapy neoadjuvant therapy for locally advanced pancreatic cancer.

Timeline

Start
2024-05-01
Primary completion
2027-01-10
Completion
2027-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadumilimab Unknown 375 mg —
Subject Gemcitabine Small molecule 1000 mg/m2 —
Subject Paclitaxel Small molecule 125 mg/m2 —
Subject sargramostim Protein / enzyme biologic 200 ug Subcutaneous

Indications

pancreatic ductal adenocarcinoma